Bioindustrial Innovation Canada (BIC) Grant Brief ### 📋 Eligible Entities - Canadian-controlled private corporations (CCPCs and other private companies) - Small and medium-sized enterprises (SMEs) with significant Canadian operations - Start-ups and scale-ups in the bioindustrial sector - Joint ventures involving eligible Canadian companies - Companies must demonstrate: - Active operations in Canada - Capacity to develop and commercialize clean technology solutions - Commitment to net-zero carbon economy transition - Non-eligible: Large multinational corporations, government agencies, non-profits (unless operating as commercial entities) ### 💰 Funding Details - Grant structure: Non-repayable financial contribution (grant-based, not a loan) - Funding range: Varies by project phase and strategic priority; typically $250,000 to $5+ million per project - Cost-sharing requirement: Generally 50% company contribution (cash or in-kind) required; federal funding covers remaining eligible costs - Repayability: Non-repayable grant; no loan component - Funding availability: Multi-year program with periodic application intake windows - Budget allocation: Prioritizes high-impact commercialization initiatives with demonstrated market potential ### 🛠️ Approved Expenses - R&D and technology development payroll and contracting - Commercialization activities (market research, business planning, regulatory navigation) - Intellectual property development (patents, trademarks, licensing strategies) - Technology adoption and integration systems - Feasibility studies and technical assessments - Equipment and infrastructure directly supporting innovation - Professional services (consulting, engineering, legal for IP protection) - Supply chain development for sustainable materials - Pilot and demonstration projects for clean technology scale-up - Training and capacity building for innovation teams ### ⚠️ Conditions & Milestones - Application requirements: - Detailed business case demonstrating net-zero carbon impact - Clear commercialization pathway and timeline - Financial projections and market analysis - Letters